### C – 647



Public Health Agence de santé Agency of Canada

publique du Canada

# Antimicrobial Resistance in Streptococcus pneumoniae Isolated in Canada: Comparison of **Blood and Respiratory Isolates, CANWARD 2007-2014** A.R. GOLDEN<sup>1</sup>, H.J. ADAM<sup>1,2</sup>, M. BAXTER<sup>1</sup>, K.A. NICHOL<sup>2</sup>, I. MARTIN<sup>3</sup>, W. DEMCZUK<sup>3</sup>, M. GILMOUR<sup>1,3</sup>, J.A. KARLOWSKY<sup>1,2</sup>, D.J. HOBAN<sup>1,2</sup>, G.G. ZHANEL<sup>1</sup>,

and the CANADIAN ANTIMICROBIAL RESISTANCE ALLIANCE (CARA) <sup>1</sup>University of Manitoba, <sup>2</sup>Diagnostic Services Manitoba, and <sup>3</sup>National Microbiology Laboratory, Winnipeg, Canada



DIAGNOSTIC SERVICES SERVICES DIAGNOSTIC MANITOBA MANITOBA

# **ABSTRACT**

Background: The goal of this study was to determine the serotype distributions and antimicrobial susceptibilities of Streptococcus pneumoniae (SPN) collected from blood and respiratory infections across Canada in 2007-2014.

Methods: S. pneumoniae strains were obtained from Canadian hospitals as part of the ongoing national surveillance study, CANWARD. SPN were serotyped using the Quellung method. Antimicrobial susceptibility testing was performed using the CLSI broth microdilution method. Multi-drug resistance (MDR) was defined as resistance to ≥3 structurally unrelated classes of antimicrobials

**Results:** 2,309 SPN isolates were collected during the CANWARD 2007-14 study; 1,497 (65%) were obtained from respiratory samples and 812 (35%) from blood samples. The 10 most common serotypes from respiratory isolates were 3, 11A, 19A, 22F, 19F, 23A, 6C, non-typeable, 35B and 23B. The 10 most common serotypes from blood were 19A, 3, 22F, 7F, 4, 5, 12F, 11A, 8 and 9N. Antimicrobial susceptibilities were: 78% (respiratory isolates)/82% (blood isolates) for clarithromycin (CLR), 92/95% for clindamycin (CLD), 85/91% for doxycycline (DOX), 99/99% for levofloxacin, 82/89% for penicillin (PEN, oral penicillin V breakpoints), 84/87% for trimethoprimsulfamethoxazole (SXT) and 99/100% for ceftriaxone (non-meningitis breakpoints). Isolates from blood demonstrated 4.4% MDR, primarily to CLR, CLD, DOX, PEN and SXT in serotype 19A. A variety of MDR patterns were observed in 8.6% of respiratory isolates, predominantly in serotypes 15A, 19A, 19F and non-typeable isolates. MDR in respiratory isolates was statistically significantly higher than in blood isolates (p<0.001).

Conclusions: The top 10 SPN serotypes causing respiratory versus blood infections in Canada in 2007-2014 were different, with the exception of 3, 11A, 19A and 22F. SPN from respiratory samples demonstrated lower antimicrobial susceptibilities and higher MDR in a greater diversity of serotypes than SPN isolated from blood.

### BACKGROUND

Streptococcus pneumoniae is a Gram-positive pathogen responsible for a number of both noninvasive (pneumonia, otitis media) and invasive (meningitis, bacteremia) manifestations of disease <sup>1</sup>. Over 90 different capsular types of *S*. pneumoniae have currently been described; these serotypes differ in their ability to invade the bloodstream based on their ability to illicit an immune response, resist phagocytosis and avoid complement<sup>2</sup>. For this reason, invasive and noninvasive serotypes of S. pneumoniae tend to differ.

Episodes of invasive pneumococcal disease are often transient; however, pneumococcal carriage is frequently long-term. Due to this lengthy occupation of the nasopharynx, these noninvasive serotypes are exposed to prolonged antimicrobial pressure, which can lead to the selection of antimicrobial resistant strains. Studies have shown that there is a correlation between the frequency of serotype isolation from the nasopharynx and the likelihood of antimicrobial resistance<sup>2</sup>.

The objective of this study was to determine the serotype distributions and antimicrobial susceptibilities of S. pneumoniae collected from blood and respiratory infections across Canada in 2007-2014.

### REFERENCES

- 1. Lynch JP and Zhanel GG. Semin Respir Crit Care Med. 2009; **30**(2): 210-38.
- 2. Hausdorff WP et al. Lancet Infect Dis. 2005; 5(2):83-93.
- 3. CLSI. Methods for dilution and antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard – 10<sup>th</sup> edition. M07-10. Wayne, PA. CLSI 2015.
- 4. CLSI. Performance standards for antimicrobial susceptibility testing; 25<sup>th</sup> informational supplement. M100-S25. Wayne, PA. CLSI 2015.

# **MATERIALS & METHODS**

### **Isolate Collection**

S. pneumoniae isolates from blood and respiratory cultures were collected as a part of the CANWARD study from 2007 to 2014, inclusive. In brief, tertiary-care medical centres were asked to submit clinical isolates (consecutive, one per patient per infection site) from both inpatients and outpatients attending hospital clinics, emergency rooms, surgical/medical wards and intensive care units. Centres submitted their first 100 respiratory isolates and first 10 blood isolates per month, for 10 months. Isolates were shipped to the coordinating laboratory (Health Sciences Centre, Winnipeg, Canada) where they were subcultured onto appropriate media and stocked in skim milk at -80°C.

### Antimicrobial Susceptibility Testing and Serotyping

Antimicrobial susceptibility testing was performed on 2,309 S. pneumoniae isolates using broth microdilution and methods described by the Clinical and Laboratory Standards Institute (CLSI) <sup>3</sup>. Minimum inhibitory concentrations were interpreted using CLSI criteria <sup>4</sup>. MDR was defined as resistance to  $\geq$ 3 antimicrobial classes. Isolates resistant to ≥5 antimicrobial classes were considered XDR. Serotyping was performed using the Quellung reaction, with pool, group, type and factor specific antisera (Statens Serum Institut, Copenhagen, Denmark).

# CONCLUSIONS

- respiratory and blood top ten serotypes.
- patterns in a greater diversity of serotypes (17 vs. 10).
- levofloxacin, penicillin and trimethoprim-sulfamethoxazole.

# ACKNOWLEDGMENTS


The authors would like to thank the participating centres, investigators and laboratory site staff for their continued support:


Dr. D. Roscoe – Vancouver Hospital, Vancouver; Dr. J. Fuller – University of Alberta Hospital, Edmonton; Dr. J. Blondeau – Royal University Hospital, Saskatoon; Drs. D. Hoban/G. Zhanel – Health Sciences Centre, Winnipeg; Dr. M. John – London Health Sciences Centre, London; Dr. S. Poutanen – University Health Network & Mount Sinai Hospital, Toronto; Dr. L. Matukas – St. Michael's Hospital, Toronto; Dr. C. Lee – St. Joseph's Hospital, Hamilton; Dr. F. Chan – Children's Hospital of Eastern Ontario, Ottawa; Dr. M. Desjardins – The Ottawa Hospital, Ottawa; Dr. M. Bergevin – Cité de la Santé de Laval, Laval; Dr. M. Laverdière – Hôpital Maisonneuve-Rosemont, Montreal; Dr. V. Loo – Montreal General Hospital, Montreal; Dr. V. Loo – Royal Victoria Hospital, Montreal; Dr. M. Goyette - CHRTR Pavilion Ste. Marie, Trois-Rivières; Dr. R. Pelletier -L'Hotel-Dieu de Quebec, Quebec City; Dr. M. Kuhn – South East Regional Health Authority, Moncton; Dr. R. Davidson – Queen Elizabeth II HSC, Halifax.

1. The ten most common serotypes varied between respiratory and blood S. pneumoniae. Serotypes 3, 11A, 19A and 22F were common between

2. Respiratory isolates demonstrated lower antimicrobial susceptibilities than isolates from blood. Respiratory isolates also demonstrated a higher percentage of MDR (8.6%) than blood isolates (4.4%), with more MDR

3. The most common MDR serotypes were 15A, 19A, 19F and non-typeable. Two serotype 19A isolates (one respiratory and one blood) were found to be XDR, with resistance to clarithromycin, clindamycin, doxycycline,








Table 2. Antimicrobial susceptibilities of S. pneumoniae collected from respiratory and blood samples.

	Antimicrobial Susceptibilities (%)		
	Respiratory	Blood	
Clarithromycin	77.7	81.6	
Clindamycin	91.7	95.0	
Ceftriaxone (meningitis)	99.1	99.7	
Ceftriaxone (non-meningitis)	99.7	100	
Doxycycline	85.1	90.9	
Levofloxacin	98.7	99.3	
Penicillin (meningitis)	80.6	87.8	
Penicillin (non-meningitis)	99.8	100	
Trimethoprim- sulfamethoxazole	83.5 87.4		

collected in 2007-14, 1,497 (65%) were obtained from respiratory samples, while 812 (35%) were obtained from blood samples. The top 10 serotypes collected differed between respiratory and blood isolates (Figure 2). Respiratory isolates demonstrated 8.6% MDR, which was statistically significantly higher than blood isolates (4.4%, p<0.001). Ten blood serotypes were MDR, most commonly 15A and 19A. Seventeen respiratory serotypes were MDR, with 15A, 19A, 19F and non-typeable isolates being most common. Only serotype 19A demonstrated an XDR pattern.

### ICAAC/ICC 2015, San Diego, CA, September 17-21, 2015

## RESULTS

Figure 1. Serotypes identified from a) respiratory isolates and b) blood isolates; organized from most common to least common, broken down by number of isolates resistant to 0 – 6 classes of antimicrobials (β-lactams,

Of the 2,309 S. Table 2. Respiratory and blood serotypes demonstrating MDR (resistance to 3 or more antimicrobial classes) or XDR (resistance to 5 pneumoniae isolates or more antimicrobial classes, italicized) pattern

MDR/XDR Pattern(s) in Respiratory Isolates	Number of Respiratory Isolates	Serotype	Number of Blood Isolates	MDR/XDR Pattern(s) in Blood Isolates
CLR, CLD, DOX (7)	7	6A/B/C	1	CLR, CLD, DOX (1)
CLR, PEN, SXT (2) CLR, CLD, DOX, PEN, SXT (1)	3	9V	-	-
CLR, CLD, DOX (1)	1	11A	1	CLR, CLD, DOX (1)
CLR, CLD, DOX, LEV (1) CLR, CLD, DOX, PEN (1) CLR, CLD, DOX, SXT (1)	3	14	1	CLR, PEN, SXT (1)
CLR, CLD, DOX (17) CLR, DOX, PEN (1) CLR, DOX, SXT (1) CLR, CLD, DOX, PEN (2)	21	15A/B/C	7	CLR, CLD, DOX (7)
CLR, CLD, DOX (7) CLR, DOX, PEN (2) CLR, DOX, SXT (2) CLR, CLD, DOX, SXT (4) CLR, CLD, PEN, SXT (2) CLR, DOX, PEN, SXT (1) CLR, CLD, DOX, PEN, SXT (28) CLR, CLD, DOX, LEV, PEN, SXT (1)	47	19A/F	21	CLR, CLD, DOX (6) CLR, DOX, PEN (2) CLR, PEN, SXT (1) CLR, CLD, DOX, SXT (1) CLR, DOX, PEN, SXT (1) CLR, CLD, DOX, PEN, SXT (9) CLR, CLD, DOX, LEV, PEN, SXT (1)
CLR, PEN, SXT (1) CLR, CLD, DOX, SXT (1)	2	22F	1	CLR, CLD, DOX, PEN, SXT (1)
CLR, CLD, DOX	7	23A/F	1	CLR, DOX, PEN , SXT (1)
CLR, CLD, DOX	2	33F	-	-
CLR, DOX, SXT (4) CLR, CLD, DOX, SXT (1)	5	35A/B/C	1	CLR, DOX, SXT (1)
CLR, CLD, DOX (9) CLR, DOX, SXT (1) CLR, PEN, SXT (1) CLR, CLD, DOX, SXT (2) CLR, DOX, LEV, SXT (2) CLR, CLD, DOX, PEN, SXT (2)	17	ΝΤ	-	-

CANADIAN ANTIMICROBIAL RESISTANCE ALLIANCE



### www.can-r.ca



/, Health Sciences Centre Sherbrook St. 1B R3A 1R9 none: 204-787-4684 Email: umgoldea@myumanitoba.ca